MetaCap

Latigo Biotherapeutics (LTGO) vs Verastem (VSTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Latigo Biotherapeutics is the larger company by market cap ($861.9 million vs $797.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LTGO-28.77%VSTM-6.08%
+54%+9%-35%
Aug 7, 20261 yearNov 20, 2026
LTGO-28.77%VSTM-6.08%
+53%+9%-35%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LTGO versus VSTM key metrics
MetricLTGOVSTM
Share price$13.00$6.33
Market cap$861.89M$797.67M
1-day change-1.81%-7.73%
YTD return—-18.01%
1-year return—-36.70%
5-year return—-80.32%
EPS (TTM)$-6.07$-1.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$30.91M
Revenue growth (YoY)—+209.14%
Net income (latest FY)—$-209.47M
Operating margin—-550.33%
Net margin—-677.59%
52-week high$25.93$10.82
52-week low$10.24$3.43
Distance from 52-week high-49.87%-41.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+301.92%+172.04%
Average volume309.60K3.53M
Shares outstanding66.30M126.01M
Employees66102
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Latigo Biotherapeutics

LTGO stock →

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

About Verastem

VSTM stock →

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

LTGO vs VSTM FAQ

Which is bigger, Latigo Biotherapeutics or Verastem?

Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $861.89M compared with $797.67M for Verastem (VSTM).

Are Latigo Biotherapeutics and Verastem in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons